A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome

Neurology

Volumn 54, Issue 3, 2000, Pages 603-607

  Sanders, Donald B ^a   Massey, Janice M ^a   Sanders, Linda L ^a   Edwards, Lloyd J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

3,4 Diaminopyridine; Eaton myasthenic syndrome; Lambert; Neuromuscular transmission disorders

Indexed keywords

3,4 DIAMINOPYRIDINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EATON LAMBERT SYNDROME; HUMAN; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TINGLING;

EID: 0034620493     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.3.603     Document Type: Article

References (16)

1. Lundh H, Nilsson O, Rosén I. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine. Eur Arch Psychiatry Neurol Sci 1985;234:374-377.
2. Sanders DB, Howard JF Jr, Massey JM. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. Ann NY Acad Sci 1993;681:588-590.
3. Palace J, Wiles CM, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 1991;54:1069-1072.
4. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-1571.
5. Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of the motor unit. JAMA 1957; 163:1117-1124.
6. Tim RW, Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton syndrome. Muscle Nerve 1994;17:995-1001.
7. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724.
8. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.
9. Ackerman MJ, Clapham DE. Ion channels: basic science and clinical disease. N Engl J Med 1997;336:1575-1586.
10. Lundh H, Nilsson O, Rosén I. Novel drug of choice in Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 1983;46: 684-687.
11. Sanders DB, Massey JM, Howard JF Jr. 3,4-Diaminopyridine in myasthenia gravis and Lambert-Eaton syndrome. Neurology 1989;39(suppl 1):267.
12. Howard JF, Weiss AS, Donovan MK, Cheshire WP, Braun TG. 3,4-Diaminopyridine effects on compound muscle action amplitudes in a patient with botulism. Muscle Nerve 1992;15: 1202-1203.
13. Molgó J, Guglielmi JM. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Pflugers Arch 1996;431:295-296.
14. Anlar B, Varli K, Ozdimir E, Ertan M. 3,4-Diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial. J Child Neurol 1996;11:458-461.
15. Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann NY Acad Sci 1998;841:811-816.
16. Lundh H, Nilsson O, Rosén I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 1993;88:136-140.